ILB
Asset Logo

iShares Government Inflation Etf

๐Ÿ‡ฆ๐Ÿ‡บ ASX

NULL AUSTRALIA

NULL INCOME

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ“™ Holdings

๐Ÿ’ฐ Distributions

๐Ÿ’ต Cost

๐Ÿƒ Esg

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

N/A
Annual Growth

5 years average annual growth

๐Ÿ’ฐ

0.62%
Annual distribution yield

Based on the most recent distribution

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

11
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

ILB.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The fund aims to provide investors with the performance of the Bloomberg AusBond Inflation Government 0+ Yr Index, before fees and expenses. The index is designed to measure the performance of a segment of the Australian bond market comprised of inflation-linked fixed income securities.

๐Ÿ“ View Factsheet

๐Ÿ“ˆ Performance

Price History

+25.33%

1M

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ“™ Top Holdings

Show more
AUSTRALIA (COMMONWEALTH OF) RegS
7.12%
NEW SOUTH WALES TREASURY CORP
4.47%
QUEENSLAND TREASURY CORP
0.50%
AUST CAPITAL TERRITORY
0.36%
AUD CASH
0.01%
TREASURY CORP VICTORIA
0.01%

Updated as of 13 May 2023

Industry Exposure
๐Ÿ“™ Other
100%
Country Exposure
๐Ÿ‡ฆ๐Ÿ‡บ Australia
100%

๐Ÿ’ฐ Distributions

Payouts

๐Ÿ’ฐ Annual Distribution Yield*

0.62%

๐Ÿ’ฐ Annual Distribution Earnings Per $1,000 invested**

$6.17

๐Ÿ’ฐ Most Recent Distribution Franked Percentage Estimate

0.00%

๐Ÿ’ฐ Average Distribution Franked Percentage Estimate

0.00 %

๐Ÿ’ฐ Distribution reinvestment

Learn more

* Based on the most recent distribution

** Calculated by multiplying the most recent distribution yield by $1,000

Distribution History

1Y

5Y

10Y

Graph

Table

Year
Yearly Distribution Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$0.21

0.00%

2022

$1.01

0.00%

2021

$0.71

0.00%

2020

$1.32

0.00%

2019

$1.78

0.00%

2018

$1.12

0.00%

2017

$1.01

0.00%

2016

$1.58

0.00%

2015

$1.97

0.00%

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

0.18%
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$125.34

๐Ÿ’ฐ Price To Earnings Ratio

0.00

๐Ÿ’ฐ Price To Book Ratio

0.00

๐Ÿ’ฐ Leveraged

No

๐Ÿ’ฐ Inverse

No

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in ILB

11

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in ILB

591 days
ILB investor breakdown
๐Ÿ’ต Income of investors

More than 200k

17%

150k - 200k

17%

100k - 150k

17%

50k - 100k

22%

Less than 50k

28%
๐Ÿ‘ถ Age of investors

18 - 25

9%

26 - 34

45%

35 - 90

45%
๐Ÿ™‹ Legal gender of investors

Female

45%

Male

55%

Pearlers who invest in ILB also invest in...

Vanguard Australian Shares Index Etf

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ“Š Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

Find Out More

VAP.AX was created on 2010-10-11 by Vanguard. The fund's investment portfolio concentrates primarily on real estate equity. Vanguard Australian Property Securities Index Fund seeks to track the return of the S&P/ASX 300 A-REIT Index before taking into account fees, expenses and tax.

๐Ÿ“Š Share price

$79.00 AUD

NULL AUSTRALIA

NULL SMART BETA

NULL PROPERTY

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

๐Ÿ“Š Share price

$43.11 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

๐Ÿ“Š Share price

$120.79 AUD

NULL AUSTRALIA

NULL BETA

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ“Š Share price

$104.08 AUD

NULL GLOBAL

NULL EX AUSTRALIA

NULL BETA

Want more shares? Try these...

ILC.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 536.73m in AUM and 21 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of the 20 largest Australian securities listed on the ASX.

๐Ÿ“Š Share price

$27.79 AUD

NULL AUSTRALIA

NULL BETA

Iluka Resources Ltd. engages in the exploration, development, mining, processing, marketing, and rehabilitation of mineral sands products. The company is headquartered in Perth, Western Australia and currently employs 950 full-time employees. The Companyโ€™s principal activity is engaged in the exploration, development, mining, processing and marketing of minerals, and rehabilitation operations. The Companyโ€™s segments include Jacinth-Ambrosia/Mid West (JA/MW), Cataby/South West (C/SW) and United States/Murray Basin (US/MB). JA/MW segment comprises the mining operations at Jacinth-Ambrosia located in South Australia, and associated processing operations at the Narngulu mineral separation plant in mid-west Western Australia. C/SW segment comprises mining activities at Cataby and processing of ilmenite at Synthetic Rutile Kiln 2, both located in Western Australia. US/MB segment comprises rehabilitation obligations in the United States (Florida and Virginia) and certain idle assets located in Australia (Murray Basin). The company sells a range of titanium dioxide feedstocks, zircon products and rare earth minerals to customers in a variety of industries.

๐Ÿ“Š Share price

$11.46 AUD

IKO.AX was created on 2000-05-09 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with the performance of the MSCI Korea 25/50 Index, before fees and expenses. The index is designed to measure the performance of Korean large-, mid- & small- capitalisation companies

๐Ÿ“Š Share price

$98.37 AUD

NULL EX US

NULL EX JAPAN

NULL ASIA

NULL EX AUSTRALIA

NULL BETA

Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is engaged in drug research and repurposing. The company is focused on developing preventative or therapeutic drugs for viral infections. The firm's lead asset, ISLA-101 is developed by its subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The drug also has the potential to be used to prevent or treat a number of viruses including dengue, Zika and chikungunya, and other diseases rife in tropical climates. The firm is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm's subsidiary is Isla Pharmaceuticals Inc.

๐Ÿ“Š Share price

$0.13 AUD
Compare
Add to watchlist